Viking Therapeutics, Inc.

As of October 31, 2025, Viking Therapeutics, Inc. shows a mildly bullish technical trend driven by short-term indicators, despite mixed signals in longer timeframes and underperformance compared to the S&P 500 year-to-date and over the past year.

As of October 31, 2025, Viking Therapeutics shows a mildly bullish trend with strong short-term performance, but caution is advised due to mixed signals in longer-term indicators.

As of October 31, 2025, Viking Therapeutics, Inc. shows a mildly bullish trend driven by weekly MACD and moving averages, despite a bearish monthly outlook, with recent returns outperforming the S&P 500 over the past week and month.

As of October 3, 2025, Viking Therapeutics, Inc. shows a mildly bearish trend overall, with daily moving averages indicating bearishness, while it has outperformed the S&P 500 recently, but has significantly negative year-to-date and one-year returns.

As of October 3, 2025, Viking Therapeutics, Inc. shows a mildly bearish trend with mixed signals, having outperformed the S&P 500 recently but significantly underperformed year-to-date and over the past year.

As of October 3, 2025, Viking Therapeutics, Inc. shows a mildly bearish technical trend with mixed signals across indicators, having outperformed the S&P 500 recently but significantly underperformed year-to-date and over the past year.

As of September 10, 2025, Viking Therapeutics, Inc. is in a bearish trend with strong MACD signals and significant underperformance, showing a 1-month return of -38.13% and a 1-year return of -59.60% compared to the S&P 500.

As of April 22, 2025, Viking Therapeutics, Inc. shows a mildly bearish trend due to mixed signals from key indicators, with weekly MACD and KST mildly bullish but monthly indicators leaning bearish.

As of March 2022, the management team of Viking Therapeutics, Inc. includes Dr. Lawson Macartney (Independent Chairman), Dr. Brian Lian (President and CEO), and Directors Matthew Foehr, S. Kathy Rouan, Charles Rowland, and J. Matthew Singleton. They oversee the company's strategic direction and operations.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. It has a market cap of approximately $2.97 billion and reported a net profit loss of $46 million as of March 2025.

As of Jun 18, Viking Therapeutics, Inc. has a market capitalization of $2.97 billion, with net sales of $0 and a net profit of -$128.24 million over the last four quarters. The company reported shareholder's funds of $880.28 million and total assets of $908.32 million as of Dec 24.